CRISPR Therapeutics
CRSP
181 hedge funds and large institutions have $1.29B invested in CRISPR Therapeutics in 2019 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 44 increasing their positions, 36 reducing their positions, and 29 closing their positions.
45% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 29
39% more capital invested
Capital invested by funds: $929M → $1.29B (+$361M)
22% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 36
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
16% more call options, than puts
Call options by funds: $30.6M | Put options by funds: $26.4M
6% more funds holding
Funds holding: 170 → 181 (+11)
2.07% more ownership
Funds ownership: 49.75% → 51.82% (+2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
+$57.2M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$32.4M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$28M |
| 4 |
JP Morgan Chase
New York
|
+$5.09M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$10.7M |
| 2 |
OTPPB
Ontario Teachers' Pension Plan Board
Toronto,
Ontario, Canada
|
-$10.4M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$8.99M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$7.99M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.1M |
CRSP Hedge Fund Activity: Q2 2019 in Review
181 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2019, worth a combined $1.29B — up 39% from $929M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new CRSP positions and 29 closed out — a net gain of 13 holders — while 44 added to existing stakes and 36 trimmed.
The largest buyer was Nikko Asset Management Americas, adding an estimated $57.2M. The largest seller was EcoR1 Capital, cutting an estimated $10.7M.
- 181 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2019, up from 170 in Q1 2019.
- Funds reported $1.29B of CRISPR Therapeutics stock for Q2 2019, up 39% quarter-over-quarter.
- 42 funds opened new CRISPR Therapeutics positions in Q2 2019 and 29 closed out, a net change of +13 holders.
- The largest CRISPR Therapeutics buyer in Q2 2019 was Nikko Asset Management Americas, an estimated $57.2M added.
- The largest CRISPR Therapeutics seller in Q2 2019 was EcoR1 Capital, an estimated $10.7M sold.
Based on aggregated 13F filings for Q2 2019.